Morgan Stanley analyst David Risinger upgraded Alkermes to Equal Weight from Underweight while lowering his price target for the shares to $20 from $30. The stock has underperformed, and recent developments eliminated the worst-case scenarios for Vumerity trial results and Vivitrol's patent, Risinger tells investors in a research note. Although cancer pipeline candidate ALKS 4230 could still disappoint, consensus expectations are low due to a questionable profile, adds the analyst. He believes Alkermes' long-term risk to royalty streams is balanced by its pipeline or cost savings optionality at current share levels.